General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Excreted Unchanged %
No data
Half-Life (Normalesrd) Hours
0.5-1/No data
Plasma Protein Binding %
No data
Volume Of Distribution L/Kg
0.5
Dose For Normal Renal Function
20 mg/m2 q6-8wk
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
75% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: No data, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No data
References
den Hartigh J, McVie JG, van Oort WJ, Pinedo HM. Pharmacokinetics of mitomycin C in humans. Cancer Res. 1983; 43: 5017-21. [PMID: 6411336] / Giroux L, Bettez P, Giroux L. Mitomycin-C nephrotoxicity: a clinico-pathologic study of 17 cases. Am J Kidney Dis. 1985; 6: 28-39. [PMID: 3927715]
Toxicity Notes
Nephrotoxicity. Hemolytic uremic syndrome.